SCHEMBL6444709

SCHEMBL6444709

Cn1cccc1-c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 1/20 0.73
ALDH1A1 P00352 5/20 0.59
CYP2A6 P11509 1/20 0.59
CYP2A13 Q16696 1/20 0.59
KDM4E B2RXH2 3/20 0.44
GAA P10253 1/20 0.44
NPC1 O15118 3/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX15 P16050 1/20 0.40
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326856 0.82 PCSK9 (0.53) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL28310880 0.81 PCSK9 (0.52) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL197196 0.81 PCSK9 (0.60) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL15591225 0.80 PCSK9 (0.51) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL3188837 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL11359663 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL11357896 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL1026027 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL11356121 0.76 PCSK9 (0.47) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E
SCHEMBL26529342 0.76 PCSK9 (0.47) PCSK9ALDH1A1CYP2A6CYP2A13KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110101862-B Treatment of cancer with SMAD3 inhibitors 香港中文大学 2022-11-01 CN claimed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed
CN-117342963-B 1, 4-Dicarbonyl compound, and preparation method and application thereof 上海予君生物科技发展有限公司 2025-06-17 CN disclosed
EP-4313308-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-02-07 EP disclosed
CN-117342963-A 1, 4-dicarbonyl compound, and preparation method and application thereof 上海予君生物科技发展有限公司 2024-01-05 CN disclosed
US-20230303537-A1 NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-09-28 US disclosed
EP-3265447-B1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-03-01 EP disclosed
CN-110101862-B Treatment of cancer with SMAD3 inhibitors 香港中文大学 2022-11-01 CN disclosed
WO-2022204452-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-09-29 WO disclosed
CN-107428708-B Benzoxazine low temperature curable compositions 亨斯迈先进材料美国有限责任公司 2021-11-09 CN disclosed
US-20200403167-A1 Synthesis of Platinum and Palladium Complexes as Narrow-Band Phosphorescent Emitters for Full Color Displays NATIONAL SCIENCE FOUNDATION 2020-12-24 US disclosed
EP-0328020-A2 Use of a catalyst in epoxy compositions THE DOW CHEMICAL COMPANY (US) 1989-08-16 EP disclosed
EP-0320628-A1 Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase ABBOTT LABORATORIES (US) 1989-06-21 EP disclosed
WO-1989004299-A1 FURAN AND PYRROLE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1989-05-18 WO disclosed
EP-0303206-A2 Process for the preparation of pyrroles BASF Aktiengesellschaft (DE) 1989-02-15 EP disclosed
CN-87105515-A Derivatives of phenylbutenamide compounds and preparation method thereof 1988-03-23 CN disclosed
EP-0125415-B1 PROCESS FOR THE PRODUCTION OF PYRROLES BASF Aktiengesellschaft (DE) 1986-11-26 EP disclosed
US-4560769-A CATALYTIC CYCLIZATION OF AMMONIA OR AMINE WITH BUT-2-ENE-1,4-DIOL BASF AKTIENGESELLSCHAFT (DE) 1985-12-24 US disclosed
EP-0125415-A1 Process for the production of pyrroles BASF Aktiengesellschaft (DE) 1984-11-21 EP disclosed
US-4243795-A Polyphosphazene copolymers containing N-substituted pyrrole substituents THE FIRESTONE TIRE & RUBBER COMPANY (US) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200403167-A1 Synthesis of Platinum and Palladium Complexes as Narrow-Band Phosphorescent Emitters for Full Color Displays DPYD, PAICS, PDCD11 PCSK9 4736/4885ALDH1A1 1028/4885CYP2A6 2537/4885
US-20230303537-A1 NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF NPM1, NFE2L2, MNS1 PCSK9 4756/4885ALDH1A1 2635/4885CYP2A6 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.